ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App
Shots: The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease, evaluating its safety and efficacy The FACET or Study 011 resulted in reduction of substrate (KIC GL-3) accumulation in the kidney capillaries Galafold (migalastat) 123mg is a novel PO dosage form of alpha Galactosidase A used for […]Read More
